Liraglutide for psychiatric disorders: clinical evidence and challenges

Hormone Molecular Biology and Clinical Investigation
Mehmet Akif CamkurtAntonio L Teixeira

Abstract

Obesity and diabetes are both risk factors and consequences of psychiatric disorders. Glucagon like peptide 1 (GLP-1) receptor agonists such as liraglutide are widely used in the treatment of diabetes and obesity. There are considerable amounts of preclinical studies showing the effects of liraglutide on promotion of neurogenesis, while preventing apoptosis and oxidation. Preliminary clinical evidence has suggested that liraglutide could decrease weight gain, improve cognition and prevent cognitive decline. Accordingly, liraglutide has been regarded as a potential candidate for the management of psychiatric disorders. Herein, we will discuss the association between obesity/diabetes and psychiatric disorders, and the emerging use of liraglutide in psychiatry.

References

May 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·D J DruckerJ F Habener
May 26, 2001·Diabetes Care·R J AndersonP J Lustman
Sep 5, 2003·Experimental Gerontology·Claude Messier
May 28, 2004·The Journal of Clinical Psychiatry·Susan L McElroyCharles B Nemeroff
Oct 12, 2004·Schizophrenia Research·Ann BagchiStephen Crystal
Jul 5, 2006·Archives of General Psychiatry·Gregory E SimonRonald C Kessler
Apr 11, 2009·Biological Psychiatry·Louis A ProfennoStephen V Faraone
Jul 28, 2009·Psychiatry Research·Francesca BrambillaMario Maj
Oct 6, 2009·American Journal of Alzheimer's Disease and Other Dementias·Ebrahim K NaderaliMark C Dale
Dec 29, 2009·European Journal of Pharmacology·Paula L McCleanChristian Hölscher
Jan 2, 2013·European Journal of Pharmacology·Vadivel Parthsarathy, Christian Hölscher
Oct 15, 2013·Schizophrenia Research·Nur Amirah Abdul RashidJimmy Lee
Mar 5, 2014·The International Journal of Eating Disorders·Amanda M DossatPamela K Keel
Apr 15, 2015·Obesity Research & Clinical Practice·Sarah Anne RobertNor Azmi Kamaruddin
Feb 7, 2016·European Journal of Pharmacology·Mayur KambleLalit K Gupta
Jun 6, 2016·Journal of Affective Disorders·Zhuoxian ZhaoAntonio L Teixeira
Apr 8, 2017·Diabetes, Obesity & Metabolism·Patrick M O'NeilUNKNOWN Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups
Sep 5, 2017·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Rodrigo B MansurRoger S McIntyre

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

The Medical Letter on Drugs and Therapeutics
Lancet
Christophe E M De Block, Luc F Van Gaal
The New England Journal of Medicine
Elias S Siraj, Kevin Jon Williams
© 2022 Meta ULC. All rights reserved